Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear

Journal of Psychiatric Research

Volumn 46, Issue 7, 2012, Pages 882-889

  Choi, Kwang ^a   Le, Thien ^a   McGuire, Jennifer ^a   Xing, Guoqiang ^a   Zhang, Lei ^a   Li, He ^a   Parker, Clarissa C ^b   Johnson, Luke R ^a   Ursano, Robert J ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Anxiety disorder; Childhood trauma; Endocannabinoid system; Fear extinction; Fear learning; Major depressive disorder; Posttraumatic stress disorder

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; AUTOPSY; BEHAVIOR; BRAIN DEVELOPMENT; BRAIN TISSUE; CONTROLLED STUDY; DISEASE DURATION; FEAR; FEMALE; FREEZING; GENE EXPRESSION; HUMAN; LOCOMOTION; MALE; MEMORY; MOOD; MOOD DISORDER; MOTOR ACTIVITY; MOUSE; NONHUMAN; POSTNATAL DEVELOPMENT; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS;

ADOLESCENT; ADULT; AGE FACTORS; ANIMALS; CHILD; CHILD, PRESCHOOL; CONDITIONING, CLASSICAL; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FEAR; FEMALE; FRONTAL LOBE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; INFANT; INFANT, NEWBORN; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; MOOD DISORDERS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RNA, MESSENGER; YOUNG ADULT;

EID: 84862003296     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.03.021     Document Type: Article

References (74)

1. Alger B.E., Kim J. Supply and demand for endocannabinoids. Trends in Neurosciences 2011, 34:304-315.
2. Ameri A. The effects of cannabinoids on the brain. Progress in Neurobiology 1999, 58:315-348.
3. Ashton C.H., Moore P.B. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatrica Scandinavica 2011, 124:250-261.
4. Bailey C.R., Neumeister A. Cb1 receptor-mediated signaling emerges as a novel lead to evidence-based treatment development for stress-related psychopathology. Neuroscience Letters 2011, 502:1-4.
5. Berghuis P., Dobszay M.B., Wang X., Spano S., Ledda F., Sousa K.M., et al. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proceedings of the National Academy of Sciences USA 2005, 102:19115-19120.
6. Bernard C., Milh M., Morozov Y.M., Ben-Ari Y., Freund T.F., Gozlan H. Altering cannabinoid signaling during development disrupts neuronal activity. Proceedings of the National Academy of Sciences USA 2005, 102:9388-9393.
7. Beyer C.E., Dwyer J.M., Piesla M.J., Platt B.J., Shen R., Rahman Z., et al. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiology of Disease 2010, 39:148-155.
8. Carrier E.J., Patel S., Hillard C.J. Endocannabinoids in neuroimmunology and stress. Current Drug Targets-CNS & Neurological Disorders 2005, 4:657-665.
9. Chhatwal J.P., Ressler K.J. Modulation of fear and anxiety by the endogenous cannabinoid system. CNS Spectrums 2007, 12:211-220.
10. Choi K., Le T., Xing G., Johnson L.R., Ursano R.J. Analysis of kinase gene expression in the frontal cortex of suicide victims: implications of fear and stress. Frontiers in Behavioral Neuroscience 2011, 5:46.
11. Choi K.H., Elashoff M., Higgs B.W., Song J., Kim S., Sabunciyan S., et al. Putative psychosis genes in the prefrontal cortex: combined analysis of gene expression microarrays. BMC Psychiatry 2008, 8:87.
12. Choi K.H., Higgs B.W., Wendland J.R., Song J., Mcmahon F.J., Webster M.J. Gene expression and genetic variation data implicate PCLO in bipolar disorder. Biological Psychiatry 2011, 69:353-359.
13. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
14. Crippa J.A., Zuardi A.W., Martin-Santos R., Bhattacharyya S., Atakan Z., Mcguire P., et al. Cannabis and anxiety: a critical review of the evidence. Human Psychopharmacology 2009, 24:515-523.
15. Dean B., Sundram S., Bradbury R., Scarr E., Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103:9-15.
16. Degenhardt L., Hall W., Lynskey M. Exploring the association between cannabis use and depression. Addiction 2003, 98:1493-1504.
17. Domschke K., Dannlowski U., Ohrmann P., Lawford B., Bauer J., Kugel H., et al. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. European Neuropsychopharmacology 2008, 18:751-759.
18. Eggan S.M., Lewis D.A. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cerebral Cortex 2007, 17:175-191.
19. Eggan S.M., Mizoguchi Y., Stoyak S.R., Lewis D.A. Development of cannabinoid 1 receptor protein and messenger RNA in monkey dorsolateral prefrontal cortex. Cerebral Cortex 2010, 20:1164-1174.
20. Eggan S.M., Stoyak S.R., Verrico C.D., Lewis D.A. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology 2010, 35:2060-2071.
21. Elashoff M., Higgs B.W., Yolken R.H., Knable M.B., Weis S., Webster M.J., et al. Meta-analysis of 12 genomic studies in bipolar disorder. Journal of Molecular Neuroscience 2007, 31:221-243.
22. Follesa P., Ticku M.K. NMDA receptor upregulation: molecular studies in cultured mouse cortical neurons after chronic antagonist exposure. Journal of Neuroscience 1996, 16:2172-2178.
23. Fraser G.A. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neuroscience & Therapeutics 2009, 15:84-88.
24. Galve-Roperh I., Aguado T., Rueda D., Velasco G., Guzman M. Endocannabinoids: a new family of lipid mediators involved in the regulation of neural cell development. Current Pharmaceutical Design 2006, 12:2319-2325.
25. Glass M., Dragunow M., Faull R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997, 77:299-318.
26. Gorzalka B.B., Hill M.N. Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35:1575-1585.
27. Greenberg P.E., Sisitsky T., Kessler R.C., Finkelstein S.N., Berndt E.R., Davidson J.R., et al. The economic burden of anxiety disorders in the 1990s. Journal of Clinical Psychiatry 1999, 60:427-435.
28. Griebel G., Stemmelin J., Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biological Psychiatry 2005, 57:261-267.
29. Guzman M., Sanchez C., Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. Journal of Molecular Medicine 2001, 78:613-625.
30. Harkany T., Guzman M., Galve-Roperh I., Berghuis P., Devi L.A., Mackie K. The emerging functions of endocannabinoid signaling during CNS development. Trends in Pharmacological Sciences 2007, 28:83-92.
31. Heim C., Nemeroff C.B. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biological Psychiatry 2001, 49:1023-1039.
32. Heng L., Beverley J.A., Steiner H., Tseng K.Y. Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. Synapse 2010.
33. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. Journal of Neuroscience 1991, 11:563-583.
34. Higgs B.W., Elashoff M., Richman S., Barci B. An online database for brain disease research. BMC Genomics 2006, 7:70.
35. Hill M.N., Gorzalka B.B. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS & Neurological Disorders-Drug Targets 2009, 8:451-458.
36. Hill M.N., Gorzalka B.B. Impairments in endocannabinoid signaling and depressive illness. Journal of the American Medical Association 2009, 301:1165-1166.
37. Hungund B.L., Vinod K.Y., Kassir S.A., Basavarajappa B.S., Yalamanchili R., Cooper T.B., et al. Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Molecular Psychiatry 2004, 9:184-190.
38. Kamprath K., Marsicano G., Tang J., Monory K., Bisogno T., Di Marzo V., et al. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. Journal of Neuroscience 2006, 26:6677-6686.
39. Kesner R.P., Holbrook T. Dissociation of item and order spatial memory in rats following medial prefrontal cortex lesions. Neuropsychologia 1987, 25:653-664.
40. Kessler R.C., Aguilar-Gaxiola S., Alonso J., Chatterji S., Lee S., Ustun T.B. The WHO World Mental Health (WMH) Surveys. Psychiatrie (Stuttgart) 2009, 6:5-9.
41. Koethe D., Llenos I.C., Dulay J.R., Hoyer C., Torrey E.F., Leweke F.M., et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. Journal of Neural Transmission 2007, 114:1055-1063.
42. Lafenetre P., Chaouloff F., Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacological Research 2007, 56:367-381.
43. Lazary J., Juhasz G., Hunyady L., Bagdy G. Personalized medicine can pave the way for the safe use of CB receptor antagonists. Trends in Pharmacological Sciences 2011, 32:270-280.
44. LeDoux J. The emotional brain, fear, and the amygdala. Cellular and Molecular Neurobiology 2003, 23:727-738.
45. LeDoux J.E. Emotion circuits in the brain. Annual Review of Neuroscience 2000, 23:155-184.
46. Lichtman A.H. SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. European Journal of Pharmacology 2000, 404:175-179.
47. Lipska B.K., Deep-Soboslay A., Weickert C.S., Hyde T.M., Martin C.E., Herman M.M., et al. Critical factors in gene expression in postmortem human brain: focus on studies in schizophrenia. Biological Psychiatry 2006, 60:650-658.
48. Lutz B. The endocannabinoid system and extinction learning. Molecular Neurobiology 2007, 36:92-101.
49. Lynskey M.T., Glowinski A.L., Todorov A.A., Bucholz K.K., Madden P.A., Nelson E.C., et al. Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Archives of General Psychiatry 2004, 61:1026-1032.
50. Mackay A.V., Iversen L.L., Rossor M., Spokes E., Bird E., Arregui A., et al. Increased brain dopamine and dopamine receptors in schizophrenia. Archives of General Psychiatry 1982, 39:991-997.
51. Marsicano G., Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. European Journal of Neuroscience 1999, 11:4213-4225.
52. McLaughlin R.J., Gobbi G. Cannabinoids and emotionality: a neuroanatomical perspective. Neuroscience 2011.
53. Moreira F.A., Wotjak C.T. Cannabinoids and anxiety. Current Topics in Behavioral Neurosciences 2010, 2:429-450.
54. Myers K.M., Davis M. Mechanisms of fear extinction. Molecular Psychiatry 2007, 12:120-150.
55. Newell K.A., Deng C., Huang X.F. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Experimental Brain Research 2006, 172:556-560.
56. Nissen S.E., Nicholls S.J., Wolski K., Rodes-Cabau J., Cannon C.P., Deanfield J.E., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. Journal of the American Medical Association 2008, 299:1547-1560.
57. Onaivi E.S. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. International Review of Neurobiology 2009, 88:335-369.
58. Pamplona F.A., Bitencourt R.M., Takahashi R.N. Short- and long-term effects of cannabinoids on the extinction of contextual fear memory in rats. Neurobiology of Learning and Memory 2008, 90:290-293.
59. Pamplona F.A., Prediger R.D., Pandolfo P., Takahashi R.N. The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats. Psychopharmacology (Berl) 2006, 188:641-649.
60. Parker CC, Sokoloff G, Cheng R, Palmer AA Genome-Wide Association for Fear Conditioning in an Advanced Intercross Mouse Line Behav Genet. 2012 Jan 12. [Epub ahead of print].
61. Parker C.C., Palmer A.A. Dark matter: are mice the solution to missing heritability?. Frontiers in Genetics 2011, 2:32.
62. Piomelli D. The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience 2003, 4:873-884.
63. Quirk G.J., Mueller D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 2008, 33:56-72.
64. Riebe C.J., Wotjak C.T. Endocannabinoids and stress. Stress 2011, 14:384-397.
65. Romero J., Berrendero F., Garcia-Gil L., De La Cruz P., Ramos J.A., Fernandez-Ruiz J.J. Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5'O-(thio)-triphosphate binding in the basal ganglia of aged rats. Neuroscience 1998, 84:1075-1083.
66. Sansone R.A., Sansone L.A. Psychiatric disorders: a global look at facts and figures. Psychiatry (Edgmont) 2010, 7:16-19.
67. Sundram S. Cannabis and neurodevelopment: implications for psychiatric disorders. Human Psychopharmacology 2006, 21:245-254.
68. Terranova J.P., Storme J.J., Lafon N., Perio A., Rinaldi-Carmona M., Le Fur G., et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) 1996, 126:165-172.
69. Torrey E.F., Webster M., Knable M., Johnston N., Yolken R.H. The stanley foundation brain collection and neuropathology consortium. Schizophrenia Research 2000, 44:151-155.
70. Tzavara E.T., Davis R.J., Perry K.W., Li X., Salhoff C., Bymaster F.P., et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. British Journal of Pharmacology 2003, 138:544-553.
71. Westlake T.M., Howlett A.C., Bonner T.I., Matsuda L.A., Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 1994, 63:637-652.
72. Witkin J.M., Tzavara E.T., Davis R.J., Li X., Nomikos G.G. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends in Pharmacological Sciences 2005, 26:609-617.
73. Xing G., Carlton J., Zhang L., Jiang X., Fullerton C., Li H., et al. Cannabinoid receptor expression and phosphorylation are differentially regulated between male and female cerebellum and brain stem after repeated stress: implication for PTSD and drug abuse. Neuroscience Letters 2011.
74. Zavitsanou K., Garrick T., Huang X.F. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004, 28:355-360.